πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

635 results for β€œdose” Clear

  1. Low Dose TP-05

    Tarsus Pharmaceuticals

    Healthy Volunteer

    phase 2 small molecule completed

    1 trial

  2. Low dose FRΞ± vaccine

    Marker Therapeutics

    Breast Cancer

    phase 2 mab completed

    1 trial

  3. Low dose LX2006

    Lexeo Therapeutics

    Friedreich Ataxia

    phase 2 gene therapy active

    1 trial

  4. Low dose of MRM-3379

    Mirum Pharmaceuticals International B.V.

    Fragile X Syndrome

    phase 2 small molecule active

    1 trial

  5. Low-dose ASA

    Atrium Therapeutics

    Germ Cell Tumor

    phase 2 small molecule active

    1 trial

  6. Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Two dose regimen

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    COVID-19

    phase 2 mab completed

    1 trial

  7. Low-dose experimental vaccine

    Sinovac Research and Development Co.,

    Herpes Zoster

    phase 2 mab active

    1 trial

  8. Low-dose of tetravalent inactivated enterovirus vaccine (Vero cell)

    Sinovac Research and Development Co.,

    Hand, Foot, and Mouth Disease (HFMD)

    phase 2 mab completed

    1 trial

  9. Luspatercept combined with low-dose thalidomide

    The First People's Hospital of Lianyungang

    Transfusion-dependent Ξ²-thalassemia Patients

    phase 2 small molecule active

    1 trial

  10. M5049 low dose

    Merck KGaA, Darmstadt, Germany

    Systemic Lupus Erythematosus

    phase 2 small molecule active

    1 trial

  11. Medium-dose COVID-19 Vaccine(Vero Cell),Inactivated

    Sinovac Research and Development Co.,

    COVID-19

    phase 2 mab on hold

    1 trial

  12. ORKA-001 Induction Dose

    Oruka Therapeutics

    Plaque Psoriasis

    phase 2 small molecule active

    1 trial

  13. ORMD-0801 Dose # 1

    ORAMED PHARMACEUTICALS INC.

    Diabetes Mellitus Type 2

    phase 2 small molecule completed

    1 trial

  14. ORY-2001 Low dose

    BRIGHT MINDS BIOSCIENCES INC.

    Mild to Moderate Alzheimer's Disease

    phase 2 small molecule completed

    1 trial

  15. PIPE-307 Dose A

    Contineum Therapeutics

    Relapsing Remitting Multiple Sclerosis

    phase 2 small molecule completed

    1 trial

  16. PIPE-791 Dose A

    Contineum Therapeutics

    Idiopathic Pulmonary Fibrosis

    phase 2 small molecule active

    1 trial

  17. PRAX-222 - Initial Dose

    Chongqing Precision Biotech Co., Ltd

    SCN2A-DEE

    phase 2 small molecule active

    1 trial

  18. Part A: RM-718 or placebo (matched to specific RM-718 dose cohort)

    Rhythm Pharmaceuticals Netherlands B.V.

    Hypothalamic Obesity

    phase 2 small molecule active

    1 trial

  19. Phase 1b/2, Multicenter, Open-label, Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3-DXd monotherapy and combinations in Patients with inoperable advanced breast cancer (ABC) after progression on T-DXd- (ICARUS BREAST 2)

    The George Institute

    Patients with HER2-positive (HER2-pos) (cohort 1) or HER2-low defined as a score 1+ on immunohistochemistry [IHC] or as an IHC score 2+ and negative results on in situ hybridization (ISH) (cohort 2) ABC, and any hormone receptor (HR) status, who have progressed on trastuzumab deruxtecan (T-DXd). In addition to previous T-DXd, patients with HER2-pos tumors must have received prior treatment with trastuzumab (+/- pertuzumab) and taxanes and may have received T-DM1. Patients with HER2-low tumors must have received prior treatment with taxanes. Patients with HR-positive (HR+) and HER2-low tumor must have received prior treatment with endocrine therapy and CDK4/6 inhibitors.

    phase 2 other active

    1 trial

  20. Phase I, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM14 Administered Intravenously to Patients with Advanced Solid Tumors

    Lacuna Pharma Pty Ltd

    Advanced Solid Tumors

    phase 2 other active

    1 trial

  21. RO7204239, RO7204239 Placebo, Mounjaro 12.5 mg/dose KwikPen solution for injection in pre-filled pen, Mounjaro 15 mg/dose KwikPen solution for injection in pre-filled pen, Mounjaro 5 mg/dose KwikPen solution for injection in pre-filled pen, Mounjaro 10 mg/dose KwikPen solution for injection in pre-filled pen, Mounjaro 10 mg/dose KwikPen solution for injection in pre-filled pen, Mounjaro 2.5 mg/dose KwikPen solution for injection in pre-filled pen, Mounjaro 7.5 mg/dose KwikPen solution for injection in pre-f

    Hoffmann-La Roche

    Obesity

    phase 2 small molecule active

    1 trial

  22. RTS,S/AS01B (50mcg of RTS,S and standard adult dose of AS01)

    United Therapeutics Europe Ltd

    Plasmodium Falciparum Malaria

    phase 2 mab completed

    1 trial

  23. Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell) (VLP-Polio) low adjuvant dose

    CanSino Biologics

    Poliomyelitis

    phase 2 mab active

    1 trial

  24. SSS17 Capsule (6 Dose Levels)

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Postoperative Anemia

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources